A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease

计划入组 344 人 · 首次发布于 2026 年 7 月 30 日

A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis

计划入组 220 人 · 首次发布于 2026 年 9 月 3 日

To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors

计划入组 300 人 · 首次发布于 2024 年 12 月 31 日

Novartis Doses First Patient in Phase 2 Sjögren's Trial of VAV1 Degrader MRT-6160, Triggering $50M Payment to Monte Rosa

Day One Biopharmaceuticals Advances FIREFLY-2 Trial and Reports Progress in DAY301 Study